LumiThera
LumiThera, Inc.: Innovating non-invasive ocular devices for treating acute and chronic eye disorders.
Founded
2013LumiThera, Inc.: Innovating non-invasive ocular devices for treating acute and chronic eye disorders.
LumiThera, Inc., founded with the mission to innovate non-invasive treatments for ocular diseases, focuses on developing photobiomodulation (PBM) therapies. The company aims to address both acute and chronic eye disorders, enhancing visual acuity, contrast sensitivity, and reducing central drusen volume. LumiThera's flagship product, the Valeda® Light Delivery System, is designed to treat conditions such as age-related macular degeneration (AMD). Based in Washington, LumiThera serves a global market of patients seeking advanced ocular care.
Notable figures associated with LumiThera include a distinguished management team and board of directors with extensive experience in medical devices and ophthalmology. The company has garnered significant attention and investment from key players in the healthcare sector. LumiThera's achievements include successful clinical trials demonstrating the efficacy of its PBM treatments and regulatory approvals that enable broader market access. The overall impact of LumiThera's innovations is seen in improved patient outcomes and advancements in non-invasive ocular therapies.
Companies similar to LumiThera include Luma Therapeutics, i-Lumen Scientific, Stimusil and Luminopia.
LumiThera was founded in 2013.
LumiThera's headquarters is located in Poulsbo, WA, US.
LumiThera's most recent funding round was for $5.5M (USD) in March 2022.
As of Mar 10, 2022, LumiThera has disclosed funding of $36.5M (USD). Undisclosed round amounts are excluded.
LumiThera has 19 employees as of Feb 5, 2024.
Luminopia
luminopia.com
